ArticleOncology letters2019

Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer.

Junnan Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.